Disease relevance of Macular Edema, Cystoid

• OBJECTIVE: This study aimed to investigate the incidence of cystoid macular edema and anterior uveitis associated with the use of latanoprost [1].
• PURPOSE: To study the effect of acetazolamide on cystoid macular edema in patients with uveitis [2].
• OBJECTIVE: To evaluate whether ketorolac ophthalmic drops prescribed four times a day can be associated with improved visual acuity and prompt resolution of edema for patients with pseudophakic cystoid macular edema identified more than 24 months after cataract surgery [3].
• We examined the fundus photographs and fluorescein angiograms of 313 eyes of 264 patients with documented cystoid macular edema to establish the incidence and characteristics of associated intraretinal hemorrhages [4].
• Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia [5].

High impact information on Macular Edema, Cystoid

• Treatment of cystoid macular edema with octreotide [6].
• Inhibition of carbonic anhydrase (CA) by acetazolamide causes a decrease in the standing potential of the retinal pigment epithelium (RPE) and an increase in the rate of subretinal fluid absorption, and it may improve cystoid macular edema [7].
• Given the results and the reports of side-effects, it is difficult to justify using acetazolamide to improve retinal function in RP patients who show no evidence of cystoid macular edema [8].
• Neither cystoid macular edema nor other retinal abnormalities were evident by fluorescein angiography in any eyes during the second week of treatment [9].
• Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema [10].

Chemical compound and disease context of Macular Edema, Cystoid

• OBJECTIVE: To identify coexisting ocular diagnoses in a case series of eyes that developed cystoid macular edema (CME) associated with latanoprost therapy [11].
• Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin [12].
• Pharmacologic therapy of aphakic cystoid macular edema (ACME) in the past has included the use of topical, periocular, and systemic corticosteroids as well as inhibitors of prostaglandin synthesis [13].
• CONCLUSIONS: Chronic pseudophakic cystoid macular edema identified more than 24 months after cataract surgery can improve with topical ketorolac but probably requires persistent use [3].
• PARTICIPANTS: The records of nine patients who had pseudophakic cystoid macular edema more than 24 months after cataract surgery at the time treatment commenced were identified at the Wilmer Retinal Vascular Center from September 1, 1996, through March 1, 1997 [3].

Biological context of Macular Edema, Cystoid

• Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: functional vision and contrast sensitivity [14].
• When BRB breakdown occurs in human ocular disorders such as diabetic retinopathy, retinitis pigmentosa, or cystoid macular edema, staining for extravascular albumin reveals leakage through the tight junctions, an upregulation of intraendothelial vesicles, and permeation of RVE or RPE cells that have undergone degenerative changes [15].

Anatomical context of Macular Edema, Cystoid

• OBJECTIVE: To study the effect of latanoprost, a prostaglandin analog, on the blood-aqueous barrier and angiographic cystoid macular edema (CME) formation in early postoperative pseudophakias [16].
• Intermittent touch of a pseudophakos to the corneal endothelium is heralded by three signs: ciliary flush, (local) corneal dystrophy, and cystoid macular edema [17].
• Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion [18].
• Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema [19].
• Prostaglandin analogs are powerful ocular hypotensive agents that may also be associated with a breakdown of the blood-retinal barrier and cystoid macular edema [20].

Gene context of Macular Edema, Cystoid

• A 30-year-old woman presenting with VHL disease and multiple RHB on her only eye, refractory to conventional treatments, had decreased visual acuity due to cystoid macular edema (CME) [21].
• BACKGROUND: Dominantly inherited cystoid macular edema was described as a clinically distinct form of macular dystrophy with an onset at approximately age 30 years with slow progression over the ensuing decades [22].
• It may be useful to investigate vascular endothelial growth factor antagonists as a treatment for uveitis-associated cystoid macular edema [19].
• One of the patients with neonatal adrenoleukodystrophy also had an anterior subcapsular cataract and cystoid macular edema [23].
• Somatostatin for Uveitic Cystoid Macular Edema (CME) [24].

Analytical, diagnostic and therapeutic context of Macular Edema, Cystoid

• Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction [3].
• The national, prospective, randomized vitrectomy study for chronic aphakic cystoid macular edema. Progress report and comparison between the control and nonrandomized groups [25].
• PURPOSE: To evaluate the effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of angiographic cystoid macular edema (CME) after cataract surgery and intraocular lens (IOL) implantation [26].
• Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery [27].
• PURPOSE: To study prospectively using optical coherence tomography (OCT) whether topical latanoprost induces retinal disorders, such as cystoid macular edema, in patients with glaucoma and a normally functioning blood-ocular barrier [28].

References